格隆汇9月15日丨上海医药(601607.SH)公布，增持主体上实国际投资有限公司(以下简称"上实国际")是 公司控股股东上海实业(集团)有限公司(以下简称"上实集团")的全资子公司，于2025年9月15日增持本公 司10万股H股，本次增持后，上实国际持有公司300,538,000股H股，占公司总股本的8.104%。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its controlling shareholder, Shanghai Shibei Group, plans to increase its holdings of the company's H-shares by 55 million to 74 million shares within the next 12 months, representing up to 2% of the company's voting shares [1] Group 1 - The increase in shareholding will be executed through Shanghai Shibei Group's wholly-owned subsidiary, Shanghai Shibei International, via the Hong Kong Stock Exchange's centralized bidding system [1] - The share purchase will not have a fixed price range and will be conducted based on market conditions [1] - The funding for this share acquisition will come from Shanghai Shibei International's own funds [1]

智通财经APP讯，上海医药(601607.SH)发布公告，基于对公司未来发展的信心，公司控股股东上实集 团计划在未来12个月内由其全资子公司上实国际，通过香港联合交易所有限公司系统以集中竞价方式增 持公司H股股份，增持股份总量5,500万股至7,400万股，不超过公司有投票权股份数的2%，本次增持不 设置固定价格区间，结合资本市场行情择机开展股票增持，资金来源为上实国际自有资金。 ...

智通财经APP讯，上海医药(601607.SH)发布公告，基于对公司未来发展的信心，公司控股股东上实集 团计划在未来12个月内由其全资子公司上实国际，通过香港联合交易所有限公司系统以集中竞价方式增 持公司H股股份，增持股份总量5,500万股至7,400万股，不超过公司有投票权股份数的2%，本次增持不 设置固定价格区间，结合资本市场行情择机开展股票增持，资金来源为上实国际自有资金。 ...

格隆汇9月15日丨上海医药(601607.SH)公布，基于对公司未来发展的信心，公司控股股东上实集团计划 在未来12个月内由其全资子公司上实国际，通过香港联合交易所有限公司系统以集中竞价方式增持公司 H股股份，增持股份总量5,500万股至7,400万股,不超过公司有投票权股份数的2%，本次增持不设置固定 价格区间，结合资本市场行情择机开展股票增持，资金来源为上实国际自有资金。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its controlling shareholder, Shanghai Industrial (Group) Co., Ltd., plans to increase its stake in the company’s H-shares through its wholly-owned subsidiary, Shanghai International Investment Co., Ltd. [1] Group 1 - The planned increase in shares will range from 55 million to 74 million shares [1] - The total shares to be acquired will not exceed 2% of the company's voting shares [1]

Core Viewpoint - The report from Citi expresses a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Group 1: Industry Insights - Potential easing of medical insurance expenditures is anticipated, which may positively impact the industry [1] - Possible optimization of centralized procurement policies is expected due to potential anti-involution measures in the healthcare sector [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a positive development for the industry [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Group 2: Company Target Price Adjustments - The target price for China National Pharmaceutical Group (国药控股) is raised from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals (上海医药) is increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical (华润医药) is decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - China National Pharmaceutical Group is identified as the preferred choice among pure distributors [1]

Core Viewpoint - The report from Credit Lyonnais indicates a structurally optimistic outlook for the Chinese pharmaceutical distribution industry despite the lack of a turnaround in the first half of the year [1] Industry Summary - Potential easing of medical insurance expenditures is anticipated, which could positively impact the industry [1] - Possible anti-involution measures in the healthcare sector are expected to optimize centralized procurement policies [1] - Strengthening of direct cash settlement from medical insurance funds is noted as a beneficial factor [1] - The domestic interest rate cut cycle is expected to improve the financial leverage of distributors [1] Company Summary - Credit Lyonnais raised the target price for China National Pharmaceutical Group (Sinopharm) from HKD 20 to HKD 24.5 [1] - The target price for Shanghai Pharmaceuticals' H-shares was increased from HKD 12.3 to HKD 14.2 [1] - The target price for China Resources Pharmaceutical was slightly decreased from HKD 5.9 to HKD 5.6, while maintaining an "outperform" rating [1] - Sinopharm is identified as the preferred choice among pure distributors by Credit Lyonnais [1]

Industry Overview - The pharmaceutical distribution industry serves as a critical link between pharmaceutical manufacturers and end consumers, characterized by a specialized division of labor [2][5] - The industry consists of upstream manufacturers producing various types of pharmaceutical products, including Western medicine, traditional Chinese medicine, medical devices, and chemical reagents [1] Cost Structure Analysis - The primary cost in the pharmaceutical distribution industry is sales cost, which includes product and raw material costs, accounting for approximately 95% of total sales costs, while other costs make up about 5% [5] Profitability Factors - Key drivers of profitability in the pharmaceutical distribution sector include sales scale and growth, gross margin levels, expense ratios, and inventory turnover [7] - Companies maintain stable gross margins through scale advantages and product structure adjustments, while controlling costs through refined management practices [7] Internet Integration - The integration of "Internet+" in the pharmaceutical distribution industry helps reduce costs and improve efficiency, allowing pharmaceutical companies to analyze order demands and pharmacies to manage inventory effectively [9] - Patients benefit from the ability to compare prices and brands online, facilitating informed purchasing decisions [9]

Drug Overview - Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, allowing the product to be marketed in the Philippines [1] - Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also be used as an adjunct treatment for depression [1] - The drug was first approved by the FDA in the United States in November 2002 and was approved for domestic sale in China in October 2004 [1] Market Competition - In the Philippines, Aripiprazole Tablets face competition from five other companies, including OTSUKA PHARM, ZYDUS PHILS. INC., and MULTICARE PHARM [2] - The total sales revenue for Aripiprazole Tablets (10 mg) in the Philippines is projected to be $2.39 million in 2024 according to IQVIA data [3] Impact on Company - The approval of Aripiprazole Tablets in the Philippines is expected to positively impact the company's efforts to expand into overseas markets and accumulate valuable experience [4]